Lipocine Stock Financials

LPCN -  USA Stock  

USD 1.10  0.03  2.65%

Understanding current and past Lipocine Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lipocine's financial statements are interrelated, with each one affecting the others. For example, an increase in Lipocine's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Lipocine's financials over time to get the whole picture.
Lipocine Working Capital is quite stable at the moment as compared to the past year. The company's current value of Working Capital is estimated at 22.16 Million.
We were able to break down thirty-one available fundamentals for Lipocine, which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Lipocine financials, including its beta, current asset, as well as the relationship between the book value per share and cash and equivalents . Given that Lipocine is a hitting penny stock territory we strongly suggest to closely look at its price to earning. Use Lipocine to protect your portfolios against small market fluctuations. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Lipocine to be traded at $1.056 in 90 days.

Lipocine Fundamentals 

With this module, you can analyze Lipocine financials for your investing period. You should be able to track the changes in Lipocine individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Lipocine is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Lipocine includes many different criteria found on its balance sheet. For example, investors should never minimize Lipocine's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Lipocine's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Lipocine.

Lipocine Cash

Chance Of Financial Distress
Less than 7
Lipocine has less than 7 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Lipocine stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Lipocine's official financial statements usually reflect Lipocine's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lipocine. For example, before you start analyzing numbers published by Lipocine accountants, it's critical to develop an understanding of what Lipocine's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Lipocine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lipocine's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lipocine's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lipocine. Please utilize our Beneish M Score to check the likelihood of Lipocine's management to manipulate its earnings.

Lipocine Company Summary

Lipocine competes with Brickell Biotech. Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. Lipocine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001535955
RegionNorth America
LocationUnited States; U.S.A
Business Address675 Arapeen Drive,
Phone801 994 7383
CurrencyUSD - US Dollar
You should never invest in Lipocine without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Lipocine Stock, because this is throwing your money away. Analyzing the key information contained in Lipocine's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Lipocine Key Financial Ratios

Generally speaking, Lipocine's financial ratios allow both analysts and investors to convert raw data from Lipocine's financial statements into concise, actionable information that can be used to evaluate the performance of Lipocine over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Lipocine reports annually and quarterly.

Lipocine Key Balance Sheet Accounts

201620172018201920202021 (projected)
Receivables38.94 K23.07 K38.51 K16.52 K19 K19.5 K
Accounts Payable245.91 K4.85 M671.28 K1.18 M1.06 M972.03 K
Total Assets27.34 M25.33 M20.85 M19.66 M25.35 M27.45 M
Current Assets27.21 M25.22 M20.81 M19.63 M25.33 M27.37 M
Assets Non Current134.19 K105.82 K42.75 K27.31 K23.75 K24.38 K
Cash and Equivalents5.56 M3.21 M13.08 M14.73 M24.22 M21.96 M
Shareholders Equity26.02 M18.98 M9.43 M6.29 M15.34 M16.27 M
Investments21.28 M18.26 M7.17 M4.34 M449.99 K461.83 K
Investments Current21.28 M18.26 M7.17 M4.34 M449.99 K461.83 K
Total Liabilities1.33 M6.35 M11.42 M13.37 M10.01 M8.11 M
Current Liabilities1.33 M6.35 M4.49 M4.96 M6.58 M5.22 M

Lipocine Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Lipocine's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201620172018201920202021 (projected)
Consolidated Income(18.97 M)(20.98 M)(11.66 M)(13.01 M)(20.96 M)(21.52 M)
Net Income(18.97 M)(20.98 M)(11.66 M)(13.01 M)(20.96 M)(21.52 M)
Operating Expenses19.19 M21.22 M11.75 M13.07 M18 M17.38 M
Operating Income(19.19 M)(21.22 M)(11.33 M)(12.9 M)(18 M)(19.42 M)

Lipocine Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Lipocine. It measures of how well Lipocine is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Lipocine brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Lipocine had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Lipocine has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201620172018201920202021 (projected)
Depreciation Amortization and Accretion31.96 K28.37 K18.59 K15.44 K3.55 K3.65 K
Net Cash Flow or Change in Cash and Cash Equivalents(14.45 M)(2.35 M)9.87 M1.65 M9.49 M10.24 M
Issuance Purchase of Equity Shares605.87 K11.23 M652.33 K13.65 M22.33 M17.82 M
Net Cash Flow from Financing605.87 K11.23 M10.65 M10.32 M20.9 M17.3 M
Net Cash Flow from Investing3.23 M3.13 M11.29 M3 M3.89 M4.2 M
Net Cash Flow Investment Acquisitions and Disposals3.3 M3.13 M11.29 M3 M3.89 M4.2 M
Net Cash Flow from Operations(18.28 M)(16.7 M)(12.08 M)(11.67 M)(15.3 M)(16.51 M)
Share Based Compensation2.37 M2.72 M1.46 M1.04 M1.37 M1.57 M

Lipocine Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Lipocine's current stock value. Our valuation model uses many indicators to compare Lipocine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lipocine competition to find correlations between indicators driving Lipocine's intrinsic value. More Info.
Lipocine is currently regarded as number one stock in current ratio category among related companies. It is considered the number one company in current valuation category among related companies reporting about  12,691,589  of Current Valuation per Current Ratio. Lipocine Current Ratio is quite stable at the moment as compared to the past year. The company's current value of Current Ratio is estimated at 3.95. Comparative valuation analysis is a catch-all model that can be used if you cannot value Lipocine by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lipocine's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lipocine's earnings, one of the primary drivers of an investment's value.

Lipocine Systematic Risk

Lipocine's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lipocine volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Lipocine correlated with the market. If Beta is less than 0 Lipocine generally moves in the opposite direction as compared to the market. If Lipocine Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lipocine is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lipocine is generally in the same direction as the market. If Beta > 1 Lipocine moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Lipocine Financials

What exactly are Lipocine Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Lipocine's income statement, its balance sheet, and the statement of cash flows. Potential Lipocine investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Lipocine investors may use each financial statement separately, they are all related. The changes in Lipocine's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lipocine's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2018 2019 2020 2021 (projected)
Accounts Payable671.28 K1.18 M1.06 M972.03 K
Receivables38.51 K16.52 K19 K19.5 K
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Lipocine is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Lipocine grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Lipocine November 30, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Lipocine help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lipocine. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lipocine based on widely used predictive technical indicators. In general, we focus on analyzing Lipocine Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lipocine's daily price indicators and compare them against related drivers.
Information Ratio(0.09)
Maximum Drawdown13.18
Value At Risk(4.31)
Potential Upside5.41
Additionally, see Stocks Correlation. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Lipocine Stock analysis

When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine Lipocine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.